Skip to content

Ultrasound-guided Acupotomy Treatment for Degenerative Cervical Radiculopathy

Feasibility, Safety, and Effectiveness of Ultrasound-guided Acupotomy Treatment for Degenerative Cervical Radiculopathy: a pilot randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0009454
Enrollment
32
Registered
2024-05-22
Start date
2024-05-27
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device, Procedure/Surgery : 1. Ultrasound-guided Acupotomy therapy 2. Conventional Physical Therapy (ICT + MW) Intervention phase : Each group will receive the assigned treatment twice a week

Sponsors

Pusan National University Korean Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) aged 30 years and older but younger than 75 years 2) pain or discomfort (numbness, paresthesia, muscle weakness) in the cervical spine and upper extremities = VAS 30mm 3) Symptom duration of 3 months or more 4) confirmed to have intervertebral disc herniation, stenosis, or spondylosis on imaging examination (CT or MRI) 5) Individuals who have received a final diagnosis of degenerative cervical radiculopathy based on comprehensive physical examination, medical history, and imaging examination results 6) Individuals who voluntarily decide to participate after being informed of the study purpose and procedure and provide written informed consent

Exclusion criteria

Exclusion criteria: 1) History or current signs of myelopathy 2) Other spinal diseases or other medical conditions (e.g., thoracic outlet syndrome, carpal tunnel syndrome, plexopathy) that could cause similar symptoms to radiculopathy 3) History of cervical spine surgery or planned surgery during the study period 4) Serious medical history of cervical spine fracture, luxation, tumor, congenital abnormality 5) Infectious or non-infectious spondylitis (e.g., ankylosing spondylitis, rheumatoid arthritis) 6) Individuals taking anticoagulants or antiplatelet drugs, or with bleeding disorders that may affect hemostasis 7) History of receiving epidural injections, nerve blocks, or other injections within 2 months 8) Individuals with acupuncture hypersensitivity, metal allergies, severe atopic dermatitis, keloid skin, or other skin hypersensitivity 9) Individuals with significant neuropsychiatric medical history or current illness 10) Individuals with a history of alcoholism or drug abuse 11) Pregnant or lactating women or those planning to become pregnant 12) Individuals who are unable to self-report consent/data or require assistance from a caregiver/researcher to do so 13) Other individuals deemed inappropriate by the clinical research coordinator

Design outcomes

Primary

MeasureTime frame
Feasibility

Secondary

MeasureTime frame
Safety assessment (Adverse effect);Visual analog scale, Upper extremity pain/discomfort;Visual analog scale, Cervical pain;painDETECT;Neck Disability Index;Depression Anxiety Stress Scale-21 (DASS-21);Euroqol-5 Dimensions-5 Levels;Patient Global Impression of change (PGIC)

Countries

Korea, Republic of

Contacts

Public ContactJihun Kim

Pusan National University Korean Medicine Hospital

kimjh2732@gmail.com@gmail.com+82-55-360-5689

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026